ID   SF188
AC   CVCL_6948
SY   SF-188; SF 188
DR   BTO; BTO_0002824
DR   EFO; EFO_0022665
DR   cancercelllines; CVCL_6948
DR   ChEMBL-Cells; CHEMBL3307445
DR   ChEMBL-Targets; CHEMBL614906
DR   Cosmic; 849884
DR   Cosmic; 1875113
DR   GEO; GSM2197886
DR   GEO; GSM2197887
DR   GEO; GSM2197888
DR   GEO; GSM2197889
DR   GEO; GSM2197890
DR   GEO; GSM2197891
DR   IARC_TP53; 5708
DR   Millipore; SCC282
DR   Progenetix; CVCL_6948
DR   PubChem_Cell_line; CVCL_6948
DR   Wikidata; Q54952896
RX   DOI=10.1007/0-306-46861-1_11;
RX   DOI=10.1016/B978-0-12-333530-2.50005-8;
RX   PubMed=2829496;
RX   PubMed=3708752;
RX   PubMed=9614553;
RX   PubMed=10416987;
RX   PubMed=19033189;
RX   PubMed=19365568;
RX   PubMed=20215515;
RX   PubMed=22570425;
RX   PubMed=25628092;
RX   PubMed=29760046;
WW   https://web.archive.org/web/20150905213317/btrctissuecore.ucsf.edu/tbank/Cell_Line%20Notice.html
CC   Doubling time: 26 hours (PubMed=19365568).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Homozygous (PubMed=9614553; PubMed=10416987).
CC   Omics: CNV analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Brain, right frontal lobe; UBERON=UBERON_0002810.
ST   Source(s): Millipore=SCC282; PubMed=22570425; Technion Genomics Center
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D10S1248: 15
ST   D12S391: 19
ST   D13S317: 13
ST   D16S539: 11
ST   D18S51: 17
ST   D19S433: 13,14
ST   D1S1656: 15,16
ST   D21S11: 31
ST   D22S1045: 11,17
ST   D2S1338: 17,22
ST   D2S441: 11
ST   D3S1358: 15,18
ST   D5S818: 11,14
ST   D7S820: 8,10
ST   D8S1179: 13,15
ST   DYS391: 11
ST   FGA: 22,22.2
ST   Penta D: 14
ST   Penta E: 10,13
ST   TH01: 9.3
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   8Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 28
//
RX   DOI=10.1007/0-306-46861-1_11;
RA   Ali-Osman F.;
RT   "Brain tumors.";
RL   (In book chapter) Human cell culture. Vol. 2. Cancer cell lines part 2; Masters J.R.W., Palsson B.O. (eds.); pp.167-184; Kluwer Academic Publishers; New York; USA (1999).
//
RX   DOI=10.1016/B978-0-12-333530-2.50005-8;
RA   Nister M., Westermark B.;
RT   "Human glioma cell lines.";
RL   (In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.17-42; Academic Press; New York; USA (1994).
//
RX   PubMed=2829496; DOI=10.1007/BF00686798;
RA   Rutka J.T., Giblin J.R., Dougherty D.V., Liu H.-C., McCulloch J.R.,
RA   Bell C.W., Stern R.S., Wilson C.B., Rosenblum M.L.;
RT   "Establishment and characterization of five cell lines derived from
RT   human malignant gliomas.";
RL   Acta Neuropathol. 75:92-103(1987).
//
RX   PubMed=3708752; DOI=10.1093/carcin/7.6.879;
RA   Bodell W.J., Aida T., Berger M.S., Rosenblum M.L.;
RT   "Increased repair of O6-alkylguanine DNA adducts in glioma-derived
RT   human cells resistant to the cytotoxic and cytogenetic effects of
RT   1,3-bis(2-chloroethyl)-1-nitrosourea.";
RL   Carcinogenesis 7:879-883(1986).
//
RX   PubMed=9614553; DOI=10.1038/sj.gt.3300605;
RA   Tada M., Sakuma S., Iggo R.D., Saya H., Sawamura Y., Fujiwara T.,
RA   Roth J.A.;
RT   "Monitoring adenoviral p53 transduction efficiency by yeast functional
RT   assay.";
RL   Gene Ther. 5:339-344(1998).
//
RX   PubMed=10416987; DOI=10.1111/j.1750-3639.1999.tb00536.x; PMCID=PMC8098486;
RA   Ishii N., Maier D., Merlo A., Tada M., Sawamura Y., Diserens A.-C.,
RA   Van Meir E.G.;
RT   "Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor
RT   suppressor genes in human glioma cell lines.";
RL   Brain Pathol. 9:469-479(1999).
//
RX   PubMed=19033189; DOI=10.1073/pnas.0810199105; PMCID=PMC2596212;
RA   Wise D.R., DeBerardinis R.J., Mancuso A., Sayed N., Zhang X.-Y.,
RA   Pfeiffer H.K., Nissim I., Daikhin E., Yudkoff M., McMahon S.B.,
RA   Thompson C.B.;
RT   "Myc regulates a transcriptional program that stimulates mitochondrial
RT   glutaminolysis and leads to glutamine addiction.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:18782-18787(2008).
//
RX   PubMed=19365568; DOI=10.1371/journal.pone.0005209; PMCID=PMC2666263;
RA   Bax D.A., Little S.E., Gaspar N., Perryman L., Marshall L.,
RA   Viana-Pereira M., Jones T.A., Williams R.D., Grigoriadis A.,
RA   Vassal G., Workman P., Sheer D., Reis R.M., Pearson A.D.J., Hargrave D.,
RA   Jones C.;
RT   "Molecular and phenotypic characterisation of paediatric glioma cell
RT   lines as models for preclinical drug development.";
RL   PLoS ONE 4:E5209-E5209(2009).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22570425; DOI=10.1093/neuonc/nos072; PMCID=PMC3367844;
RA   Bady P., Diserens A.-C., Castella V., Kalt S., Heinimann K.,
RA   Hamou M.-F., Delorenzi M., Hegi M.E.;
RT   "DNA fingerprinting of glioma cell lines and considerations on
RT   similarity measurements.";
RL   Neuro-oncol. 14:701-711(2012).
//
RX   PubMed=25628092; DOI=10.1038/bjc.2015.16; PMCID=PMC4333505;
RA   Cockle J.V., Picton S., Levesley J., Ilett E.J., Carcaboso A.M.,
RA   Short S., Steel L.P., Melcher A., Lawler S.E., Bruning-Richardson A.;
RT   "Cell migration in paediatric glioma; characterisation and potential
RT   therapeutic targeting.";
RL   Br. J. Cancer 112:693-703(2015).
//
RX   PubMed=29760046; DOI=10.1158/0008-5472.CAN-17-3691; PMCID=PMC6294442;
RA   Pal S., Kozono D., Yang X.-D., Fendler W., Fitts W., Ni J., Alberta J.A.,
RA   Zhao J., Liu K.X., Bian J., Truffaux N., Weiss W.A., Resnick A.C.,
RA   Bandopadhayay P., Ligon K.L., DuBois S.G., Mueller S., Chowdhury D.,
RA   Haas-Kogan D.A.;
RT   "Dual HDAC and PI3K inhibition abrogates NFkappaB- and FOXM1-mediated
RT   DNA damage response to radiosensitize pediatric high-grade gliomas.";
RL   Cancer Res. 78:4007-4021(2018).
//